|
Optipres Eye Drops (Betaxolol)
What is Optipres Eye Drops (Betaxolol) used for? Optipres Eye Drops (Betaxolol) are used to reduce pressure in the eye in patients with glaucoma. Reducing intraocular pressure can help to reduce the risk of blindness and nerve damage in patients with glaucoma. This medication is in a class of drugs known as beta blockers, which work by reducing the production of liquid within the eye. How should I use Optipres Eye Drops (Betaxolol)? Optipres Eye Drops (Betaxolol) should be directly applied to the eye. Patients should consult their physician, so that they can have the correct dosage prescribed for them. After administering the eye drops, you should apply gentle pressure to the corner of the eye, on the inside of the nose, for 1 minute. This will help prevent the medication from dripping out. What are the side effects of Optipres Eye Drops (Betaxolol)? Optipres Eye Drops (Betaxolol) may cause some side effects in patients who use them, such as:
Although the above mentioned side effects are not severe, you should consult your physician immediately if they persist. Other more serious side effects requiring immediate medical attention include changes in vision, light sensitivity, swollen limbs, loss of hair, breathlessness, weight gain or fainting. Please Note Strictly follow all instructions provided to you by your physician or pharmacist while using Optipres Eye Drops (Betaxolol). Optimum and safe dosage can differ based on the patient and the condition being treated. As this medication may be unsafe for certain patients, it is essential you always inform your physician if you are pregnant or breastfeeding, as well as if you have any allergies, other illnesses, or ongoing health conditions, and if you are taking any other form of medication, supplements, or herbal products. Immediately seek emergency medical care if you have any allergic or hypersensitive reaction. Common signs of a reaction include hives, swelling, skin rashes, chest pains, as well as trouble breathing or swallowing. |